Endo in a Bite

This episode reviews the cardiovascular kidney metabolic (CKM) syndrome framework introduced by the American Heart Association, which describes the interconnected progression of obesity, type 2 diabetes, chronic kidney disease, and cardiovascular disease. The discussion highlights CKM staging and emphasizes early cardiometabolic risk recognition and preventive therapy including statins, blood pressure control, glucagon like peptide 1 receptor agonists, sodium glucose cotransporter 2 inhibitors, and renin angiotensin system blockade to reduce cardiovascular and kidney complications.

This episode reviews the American Heart Association PREVENT™ cardiovascular risk calculator and its role in modern primary prevention. The discussion highlights the shift from the pooled cohorts equation to contemporary risk prediction models that incorporate kidney function, cardiometabolic risk staging, and updated population data. Emphasis is placed on risk refinement strategies including coronary artery calcium scoring and lipid biomarkers such as apolipoprotein B and lipoprotein(a). These tools help identify hidden cardiovascular risk and guide preventive lipid lowering therapy before clinical cardiovascular disease develops.

This episode reviews the 2025 ACE consensus framework for individualized obesity pharmacotherapy, moving beyond standardized algorithms toward condition based medication selection. Emphasis is placed on comorbidities, organ specific risk stratification, safety monitoring, and long term therapeutic benefit to support precision management of adiposity based chronic disease.

This episode reviews the 2025 ACE consensus approach to cost conscious obesity pharmacotherapy, emphasizing access driven treatment sequencing, payer mandated step therapy, and stage based medication selection for adiposity based chronic disease. Focus is placed on balancing clinical efficacy, affordability, and long term sustainability, with escalation and override strategies guided by therapeutic response and the presence of obesity related complications.

This episode reviews the 2025 ACE consensus on complication centric obesity management, with a focus on organ system based medication prioritization. Topics include pharmacologic selection across cardiometabolic, renal, hepatic, cardiovascular, and biomechanical complications, emphasizing outcome driven therapy rather than weight alone in adiposity based chronic disease (ABCD).

This episode reviews the 2025 ACE consensus on biologically informed lifestyle therapy for obesity and adiposity based chronic disease (ABCD), including personalized nutrition strategies to achieve and sustain an energy deficit, protein and micronutrient requirements to preserve lean mass and metabolic health, physical activity and resistance training targets for weight maintenance, the role of sleep and circadian regulation in energy balance, and the importance of addressing weight bias, stigma, and psychological comorbidities in long term obesity management.

This episode reviews the 2025 ACE consensus on therapeutic weight loss response, threshold based outcomes, early pharmacologic response assessment, and how to align intervention intensity with disease severity in adiposity based chronic disease (ABCD).

This episode reviews the clinical component of the 2025 ACE consensus, shifting from identifying excess adiposity to staging adiposity based chronic disease (ABCD). It explains how clinicians assess obesity related complications, apply disease staging independent of BMI, and account for contributing factors such as medications, endocrine causes, genetics, psychological influences, and social determinants. The episode then connects staging to individualized treatment planning and long term management within a chronic disease framework.

This episode examines the anthropometric component of the 2025 ACE consensus on obesity, emphasizing the role of BMI as a screening tool rather than a diagnostic endpoint. It outlines population specific BMI thresholds, the clinical need for assessing abdominal adiposity, and the importance of standardized waist circumference and waist to height ratio measurements in evaluating cardiometabolic risk. The discussion reinforces why body fat distribution, rather than total body weight, drives disease risk and explains when body composition testing is indicated to clarify clinical ambiguity. The episode situates these measurements within the broader ACE framework for adiposity based chronic disease (ABCD), supporting more accurate risk stratification and individualized management.

This episode introduces the 2025 ACE consensus framework for obesity, reframing the condition as adiposity based chronic disease (ABCD) rather than a numeric weight diagnosis. It reviews the shift toward person centered, complication centric care, emphasizing the role of both anthropometric and clinical assessment in diagnosis and staging. The discussion highlights obesity related complications as the primary driver of disease severity, the limitations of body mass index as an endpoint, and the importance of shared decision making and longitudinal management using lifestyle, pharmacologic, and surgical therapies to improve health outcomes and quality of life.